Skip to main content
. 2008 Dec 10;26(35):5728–5734. doi: 10.1200/JCO.2008.17.6545

Table A2.

Validation of Final Multivariable Model for Acute GVHD in Chronic Myeloid Leukemia

Variable Grade 2-4 Acute GVHD
Grade 3-4 Acute GVHD
RR 95% CI P RR 95% CI P
For recipients age 18-39 years
    Bone marrow graft 1.0 1.0
    Peripheral blood stem-cell graft 1.34 0.945 to 1.90 .1007 1.10 0.65 to 1.87 .7233
For recipients age 40+ years
    Bone marrow graft 1.0 1.0
    Peripheral blood stem-cell graft 0.81 0.58 to 1.11 .1944 1.01 0.63 to 1.64 .9599
Age for recipients of bone marrow transplants, years
    18-39 1.0 1.0
    40+ 1.55 1.18 to 2.03 .0016 1.29 0.86 to 1.93 .2179
Age for recipients of peripheral-blood stem-cell transplants, years
    18-39 1.0 1.0
    40+ 0.93 0.63 to 1.38 .7211 1.19 0.65 to 2.16 .5772
Race
    Asian/Hispanic 1.0 1.0
    White/Black 1.31 0.95 to 1.79 .0956 0.99 0.64 to 1.52 .9516
Karnofsky performance score at transplant
    90-100 1.0 1.0
    0-80 1.46 1.09 to 1.96 .0110 1.58 1.03 to 2.42 .0370
Conditioning regimen
    BuCy ± other 1.0 1.0
    CyTBI ± other 1.44 1.13 to 1.84 .0035 0.85 0.57 to 1.27 .4324
Recipient-donor cytomegalovirus status
    ≥ 1 positive 1.0 1.0
    Both negative 1.37 1.07 to 1.74 .0117 1.53 1.07 to 2.19 .0190

Abbreviations: GVHD, graft-versus-host disease; RR, relative risk; BuCy ± other, busulfan and cyclophosphamide with or without additional agents; CyTBI ± other, cyclophosphamide and total body irradiation with or without additional agents.